Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
Recent Articles
Missing the Covid boat, Junshi stumbles back to old business
1877.HK
688180.SHG
RELATED ARTICLES
-
As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
ZTE comeback stumbles on China telecoms spending slowdown
0763.HK 000063.SHE
